Adage Capital Partners GP L.L.C. Acquires New Shares in AngioDynamics, Inc. $ANGO

Adage Capital Partners GP L.L.C. acquired a new position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 100,000 shares of the medical instruments supplier's stock, valued at approximately $939,000. Adage Capital Partners GP L.L.C. owned about 0.25% of AngioDynamics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in AngioDynamics by 4.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,968 shares of the medical instruments supplier's stock valued at $201,000 after buying an additional 969 shares in the last quarter. Cerity Partners LLC boosted its stake in AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock worth $121,000 after buying an additional 2,333 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in AngioDynamics by 6.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 36,936 shares of the medical instruments supplier's stock worth $339,000 after buying an additional 2,397 shares in the last quarter. Public Employees Retirement System of Ohio boosted its stake in AngioDynamics by 5.8% in the fourth quarter. Public Employees Retirement System of Ohio now owns 70,972 shares of the medical instruments supplier's stock worth $650,000 after buying an additional 3,900 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of AngioDynamics by 2.4% during the fourth quarter. Northern Trust Corp now owns 351,365 shares of the medical instruments supplier's stock valued at $3,219,000 after purchasing an additional 8,260 shares during the period. Hedge funds and other institutional investors own 89.43% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ANGO. Wall Street Zen raised AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Canaccord Genuity Group increased their price objective on AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of AngioDynamics in a report on Wednesday, July 16th. Finally, Lake Street Capital initiated coverage on AngioDynamics in a report on Wednesday, July 16th. They set a "buy" rating and a $24.00 target price for the company. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, AngioDynamics presently has an average rating of "Buy" and a consensus target price of $19.00.

AngioDynamics Trading Down 2.8%

ANGO traded down $0.31 during trading on Friday, reaching $10.65. The stock had a trading volume of 534,075 shares, compared to its average volume of 352,209. AngioDynamics, Inc. has a one year low of $5.83 and a one year high of $13.50. The company has a market capitalization of $432.71 million, a price-to-earnings ratio of -12.83 and a beta of 0.64. The stock's 50 day moving average is $9.41 and its two-hundred day moving average is $9.59.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.The firm had revenue of $80.16 million for the quarter, compared to analysts' expectations of $74.26 million. During the same period in the prior year, the firm posted ($0.06) earnings per share. The company's quarterly revenue was up 13.0% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. On average, equities research analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.